α1A-肾上腺素能受体与增强型绿色荧光蛋白标记的活化T细胞核因子2稳定共表达细胞的构建OA北大核心CSTPCD
Establishment of cells stably co-expressing with α1A-adrenergic receptor and enhanced green fluorescent protein tagged nuclear factor of activated T cells 2
目的 建立α1A-肾上腺素能受体(α1A-AR)与增强型绿色荧光蛋白(EGFP)标记的活化T细胞核因子2(NFAT2)稳定共表达细胞.方法 ① 将pcDNA3.1-α1A-AR-3×FLAG重组质粒转染至U2OS-EGFP-NFAT2细胞,经潮霉素B(Hygro-B)200 mg·L-1 压力筛选后加入α1A-AR激动剂去甲肾上腺素(NE,10 μmol·L-1)孵育30 min,通过高内涵筛选系统检测细胞核内绿色荧光强度,验证EGFP-NFAT2 核转位,筛选得到稳定表达α1A-AR的U2OS-EGFP-NFAT2-α1A-AR细胞.②采用实时荧光定量PCR(RT-qPCR)和Western印迹法检测该细胞和对照细胞U2OS-EGFP-NFAT2中α1A-AR mRNA和蛋白的表达水平.③将U2OS-EGFP-NFAT2-α1A-AR细胞接种于96孔板,分别加入NE(10-8~10-5 mol·L-1)或α2-AR激动剂右美托咪定(DMED,10-8.8~10-5 mol·L-1)孵育30 min,通过高内涵筛选系统检测EGFP-NFAT2 核转位.④将U2OS-EGFP-NFAT2-α1A-AR细胞分为溶剂对照组、α1-AR拮抗剂萘派地尔(1 μmol·L-1)组、NE(1 μmol·L-1)组、萘派地尔+NE(各1 μmol·L-1共孵育)组、α2-AR拮抗剂阿替美唑(0.1 μmol·L-1)组、DMED(0.1 μmol·L-1)组、阿替美唑+DMED(各0.1 μmol·L-1 共孵育)组和萘派地尔+DMED(萘派地尔1 μmol·L-1 与 DMED 0.1 μmol·L-1共孵育)组,药物孵育时间均为30 min,通过高内涵筛选系统检测EGFP-NFAT2核转位,验证该细胞α1A-AR功能的特异性.结果 ①Hygro-B压力筛选得到58株U2OS-EGFP-NFAT2-α1A-AR细胞,NE 10 μmol·L-1孵育后,其中50号细胞核内绿色荧光强度最强,故选定其为稳定共表达α1A-AR和EGFP-NFAT2的U2OS-EGFP-NFAT2-α1A-AR细胞.②Western印迹法结果显示,U2OS-EGFP-NFAT2-α1A-AR细胞可明显表达α1A-AR蛋白,而对照细胞U2OS-EGFP-NFAT2中未见α1A-AR蛋白表达.RT-qPCR结果显示,该细胞在传代5~20代内α1A-AR mRNA均稳定表达,其表达水平为对照细胞的500~800倍.③NE或DMED使U2OS-EGFP-NFAT2-α1A-AR细胞中EGFP-NFAT2核转位明显增加,半数有效浓度(EC50)分别为5.94×10-7和6.15×10-8 mol·L-1.④与溶剂对照组和萘派地尔组比较,NE组U2OS-EGFP-NFAT2-α1A-AR细胞EGFP-NFAT2核转位明显增强(P<0.01),而萘派地尔+NE组EGFP-NFAT2核转位较NE组明显减弱(P<0.01).与溶剂对照组和阿替美唑组比较,DMED组EGFP-NFAT2核转位明显增强(P<0.01),阿替美唑+DMED组EGFP-NFAT2核转位与DMED组比较无明显差别,而萘派地尔+DMED组EGFP-NFAT2核转位较DMED组明显减弱(P<0.01).结论 成功构建稳定共表达α1A-AR和EGFP-NFAT2的U2OS-EGFP-NFAT2-α1A-AR细胞,可用于靶向α1A-AR化合物筛选和受体分子机制研究.
OBJECTIVE To establish the cells stably co-expressing α1A-adrenergic receptor(α1A-AR)and enhanced green fluorescent protein(EGFP)tagged nuclear factor of activated T cells 2(NFAT2)(EGFP-NFAT2)in U2OS cells.METHODS ① The pcDNA3.1-α1-AR-3×FLAG recombinant plasmid was transfected into U2OS-EGFP-NFAT2 cells.The transfected cells were selected by hygromycin B(Hygro-B,200 mg·L-1),and screened by EGFP-NFAT2 nuclear translocation assay after α1A-AR agonist norepinephrine(NE)treatment of 30 min.② The mRNA and protein expression levels of α1A-AR in the selected U2OS-EGFP-NFAT2-α1A-AR cells were examined by real-time quantitative PCR(RT-qPCR)and Western blotting.③ U2OS-EGFP-NFAT2-α1A-AR cells were treated with NE(10-8-10-5 mol·L-1)or dexmedetomidine(DMED,10-8.8-10-5 mol·L-1),respectively,for 30 min.EGFP-NFAT2 nuclear translo-cation was detected by high throughout screening assay.④ The U2OS-EGFP-NFAT2-α1A-AR cells were divided into the solvent control group,α1-AR antagonist naftopidill(1 μmol·L-1)group,NE(1 μmol·L-1)group and naftopidill+NE(co-incubation with naftopidill 1 μmol·L-1 and NE 1 μmol·L-1)group,α2-AR antagonist atipamezole(ATI,0.1 μmol·L-1)group,α 2-AR agonist DMED(0.1 μmol·L-1)group,and ATI+DMED(co-incubation with ATI 1 μmol·L-1 and DMED 0.1 μmol·L-1)group.The drug incubation time was 30 min.EGFP-NFAT2 nuclear translocation was abserved via a high throughout screening system to validate the α1A-AR function in U2OS-EGFP-NFAT2-α1A-AR cells.RESULTS ① There were 58 cell strains expressing α1A-AR in U2OS-EGFP-NFAT2 cells by EGFP-NFAT2 nuclear translocation assay.Among these cells,cells No 50 had the highest nuclear translocation function.The α1A-AR mRNA expression of cells No 50 in 5-20 generations were detected by RT-qPCR and were about 500-800 times that of U2OS-EGFP-NFAT2 cells.② The protein band of α1A-AR was also detected in cells No 50,but no band of α1A-AR was detected in U2OS-EGFP-NFAT2 cells by Western blotting.③ NE and DMED increased the relative translocation nuclear index in U2OS-EGFP-NFAT2-α1A-AR cells with ED50 5.94×10-7 and 6.15×10-8 mol·L-1,respectively.④ EGFP-NFAT2 nuclear translocation was significant in U2OS-EGFP-NFAT2-α1A-AR cells after NE addition compared with the solvent control or the naftopidill groups(P<0.01).The EGFP-NFAT2 nuclear translocation in the naftopidill+NE group was significantly decreased compared with the NE group(P<0.01).DMED significantly increased the EGFP-NFAT2 nuclear translocation compared with solvent control or the ATI groups(P<0.01).The EGFP-NFAT2 nuclear translocation in the ATI+DMED group was similar to that of the DMED group.The EGFP-NFAT2 nuclear translocation in the naftopidill+DMED group was decreased significantly compared with the DMED group(P<0.01).CONCLUSION U2OS-EGFP-NFAT2-α1A-AR cells stably co-exrepssing α1A-AR and EGFP-NFAT2 are established,which can be used for high throughout screening of biased chemicals and studies on the mechanism of α1A-AR.
王晓璇;李玉蕾;周培岚;苏瑞斌
军事医学研究院国家安全特需药品全国重点实验室,神经精神药理学北京市重点实验室,北京 100850
药学
α1A-肾上腺素能受体活化T细胞核因子2核转位去甲肾上腺素高内涵筛选系统
α1A-adrenergic receptornuclear factor of activated T cells 2nuclear translocationnorepinephrinehigh throughout screening
《中国药理学与毒理学杂志》 2024 (008)
587-594 / 8
国家自然科学基金(82273909) National Natural Science Foundation of China(82273909)
评论